Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jorge Cortes

Showing results (21-30 of 791) with videos related to

Pageof 80
Sort By:
Blood|March 18, 2025
Considerations on the dose and schedule of tyrosine kinase inhibitors for chronic myeloid leukemia: does dose matter?Mark Dalgetty, Jorge Cortes
Hematology. American Society of Hematology. Education Program|December 4, 2016
Chronic myeloid leukemia: sequencing of TKI therapiesJorge Cortes, Hagop Kantarjian
American Journal of Hematology|July 11, 2008
Philadelphia-negative acute myeloid leukemia with new chromosomal abnormalities developing after first-line imatinib treatment for chronic phase chronic myeloid leukemiaCarmen Fava, Jorge Cortes
Advances in Pharmacology (San Diego, Calif.)|October 7, 2004
Investigational agents in myeloid disordersFarhad Ravandi, Jorge Cortes
South Asian Journal of Cancer|April 4, 2015
The changing face of acute myeloid leukemia therapeutics in the elderly populationNaval Daver, Jorge Cortes
Seminars in Hematology|July 23, 2009
Optimizing first-line therapy for patients with chronic myeloid leukemiaCarmen Fava, Jorge Cortes
Blood|May 23, 2015
Introduction to the review series on acute lymphoblastic leukemiaJean Soulier, Jorge Cortes
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 13, 2005
New targeted approaches in chronic myeloid leukemiaJorge Cortes, Hagop Kantarjian
Acta Haematologica|September 18, 2014
Chronic myeloid leukemia in adolescents and young adults: patient characteristics, outcomes and review of the literatureNaveen Pemmaraju, Jorge Cortes
Hematology (Amsterdam, Netherlands)|April 18, 2012
Molecular targeted therapy in acute myeloid leukemiaNaval Daver, Jorge Cortes
Pageof 80

Showing results (21-30 of 791) with videos related to

Sort By:
Pageof 80
Blood|March 18, 2025
Considerations on the dose and schedule of tyrosine kinase inhibitors for chronic myeloid leukemia: does dose matter?Mark Dalgetty, Jorge Cortes
Hematology. American Society of Hematology. Education Program|December 4, 2016
Chronic myeloid leukemia: sequencing of TKI therapiesJorge Cortes, Hagop Kantarjian
American Journal of Hematology|July 11, 2008
Philadelphia-negative acute myeloid leukemia with new chromosomal abnormalities developing after first-line imatinib treatment for chronic phase chronic myeloid leukemiaCarmen Fava, Jorge Cortes
Advances in Pharmacology (San Diego, Calif.)|October 7, 2004
Investigational agents in myeloid disordersFarhad Ravandi, Jorge Cortes
South Asian Journal of Cancer|April 4, 2015
The changing face of acute myeloid leukemia therapeutics in the elderly populationNaval Daver, Jorge Cortes
Seminars in Hematology|July 23, 2009
Optimizing first-line therapy for patients with chronic myeloid leukemiaCarmen Fava, Jorge Cortes
Blood|May 23, 2015
Introduction to the review series on acute lymphoblastic leukemiaJean Soulier, Jorge Cortes
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 13, 2005
New targeted approaches in chronic myeloid leukemiaJorge Cortes, Hagop Kantarjian
Acta Haematologica|September 18, 2014
Chronic myeloid leukemia in adolescents and young adults: patient characteristics, outcomes and review of the literatureNaveen Pemmaraju, Jorge Cortes
Hematology (Amsterdam, Netherlands)|April 18, 2012
Molecular targeted therapy in acute myeloid leukemiaNaval Daver, Jorge Cortes
Pageof 80